Guggenheim Capital LLC Reduces Position in Edwards Lifesciences Corporation $EW

Key Points

• Guggenheim Capital LLC has reduced its position in Edwards Lifesciences by 7.1%, now holding 200,059 shares valued at approximately $14.5 million.
• Edwards Lifesciences reported earnings of $0.67 per share, exceeding analysts' expectations, and achieved a revenue of $1.53 billion for the last quarter.
• Several analysts have recently upgraded their price targets for Edwards Lifesciences, with JPMorgan Chase setting it at $85.00 and BTIG Research raising it to $100.00.

Guggenheim Capital LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 7.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,059 shares of the medical research company's stock after selling 15,347 shares during the quarter. Guggenheim Capital LLC's holdings in Edwards Lifesciences were worth $14,500,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Vega Investment Solutions bought a new stake in Edwards Lifesciences in the 4th quarter worth $27,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at about $26,000. SouthState Corp purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $29,000. Finally, Costello Asset Management INC purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $29,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $81.01 on Thursday. The business's fifty day moving average is $78.01 and its 200 day moving average is $74.88. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $47.56 billion, a price-to-earnings ratio of 11.66, a PEG ratio of 3.92 and a beta of 1.08. Edwards Lifesciences Corporation has a twelve month low of $64.00 and a twelve month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm earned $0.70 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a research note on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Finally, Truist Financial upped their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $85.90.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president directly owned 50,356 shares of the company's stock, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,584 shares of company stock worth $1,897,762. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.